Could less be more? new trial reduces breast cancer treatment for best responders
NCT ID NCT07407920
First seen Feb 20, 2026 · Last updated May 22, 2026 · Updated 9 times
Summary
This study looks at whether people with early HER2-positive or triple-negative breast cancer who had a complete response to pre-surgery treatment and have no cancer DNA in their blood can safely receive less therapy after surgery. The goal is to maintain good outcomes while reducing side effects. About 120 participants will receive a shorter course of immunotherapy or targeted therapy instead of the standard one-year regimen.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE I BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.